JPRN-UMIN000000590已完成2 期
The efficacy and the safety of gemcitabine / S-1 combination therapy in patients with advanced non-resectable or post-operative recurrent biliary tract cancer -multicenter phase II study - Phase II study of gemcitabine / S-1 combination therapy in patients with advanced biliary tract cancer
Faculty of Medicine, University of Tokyo0 个研究点目标入组 35 人开始时间: 2007年2月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients with an active concomitant infection 2) Patients with digestive ulcer or gastrointestinal bleeding 3) Patients with severe cardiovascular or renal disease 4) Patients with an active pulmonary fibrosis or interstitial pneumonia 5) Patients with uncontrollable massive pleural effusion or massive ascites 6) Patients with an active concomitant malignancy 7) Pregnant, lactating female and patients of reproductive potential who did not use effective contraception 8) Patients with a previous history of a severe drug hypersensitivity 9) Patients receiving anti-cancer drugs 10) Inappropriate patients for entry on this study in the judgement of the investigator
研究者
相似试验
已完成
2 期
The efficacy and safety of gemcitabine / cisplatin combination therapy in patients with advanced refractory biliary tract cancerAdvanced biliary tract cancer refractory to gemcitabine and S-1JPRN-UMIN000001615Faculty of Medicine, University of Tokyo20
招募中
1 期
Phase I/II study of Gemcitabine and S-1 (GS therapy) as Neoadjuvant chemoradiationtherapy for borderline resectable pancreatic cancer (Prep-03/NS014-1)Borderline resectable pancreatic cancerJPRN-UMIN000014498Study group of preoperative therapy for pancreatic cancer (PREP)40
招募中
1 期
Prep-03C535836Pancreatic cancerpancreatic cancerJPRN-jRCTs021180045nno Michiaki40
已完成
2 期
Phase II/III study of Gemcitabine and S-1 (GS therapy) as Neoadjuvant chemotherapy for resectable pancreatic cancer (Prep-02/JSAP-05)JPRN-UMIN000009634Study group of preoperative therapy for pancreatic cancer (PREP)/Japanese Study Group of Adjuvant Therapy for pancreatic Cancer (JSAP)364
招募中
1 期
Safety and Efficacy for Gemcitabine plus nab-paclitaxel with MK615 combination therapy in unresected/recurrent metastatic pancreatic cancer.: Phase I/II study (PC(UR-M) GEM/nab-PTX + MK615)pancreatic cancerJPRN-jRCTs061180074FUKUBA Nobuhiko35